Pipeline

Development status (JP)

Development stage Code name,
generic name
Indication Origin Development Remarks
Filed AK1820
(isavuconazonium sulfate)
Aspergillosis, Mucormycosis and Cryptococcosis Licensed:Basilea Pharmaceutica International Ltd, Allschwil Asahi Kasei Pharma Corporation Additional formulation
Phase III TA799, apraglutide Short bowel syndrome Licensed: VectivBio AG, an Ironwood Pharmaceuticals subsidiary VectivBio AG, an Ironwood Pharmaceuticals subsidiary Phase I in Japan was conducted by Asahi Kasei Pharma
Phase II ART-123,
recombinant thrombomodulin alfa
Chemotherapy- induced peripheral neuropathy (CIPN) In-house Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals Additional indication Joint U.S.-Japan Phase I study in progress
Phase II AK1830 Pain associated with osteoarthritis Chronic low back pain Licensed:Array BioPharma Inc., a wholly owned subsidiary of Pfizer, Inc. Asahi Kasei Pharma Corporation
Phase I AK1910 Autoimmune diseases Licensed:SBI Biotech Co., Ltd. Asahi Kasei Pharma Corporation

Development status (Global)

Development stage Code name,
generic name
Indication Origin Development Region
Phase III ART-123,
recombinant thrombomodulin alfa
Severe sepsis with coagulopathy In-house Asahi Kasei Pharma Corporation United States, Europe, etc.
Phase I ART-123,
recombinant thrombomodulin alfa
Chemotherapy- induced peripheral neuropathy (CIPN) In-house Asahi Kasei Pharma Corporation and Veloxis Pharmaceuticals United States
Phase I AK1320 Spinal fusion surgery In-house Asahi Kasei Pharma Corporation North America

Development status (licensed out)

Development stage Code name,
generic name
Indication Origin Development Region
Phase II LY3857210 Chronic Pain In-house (co-research with RaQualia Pharma Inc.) Eli Lilly and Company Global (AKP has rights to promote LY3857210 in Japan and China)
Page Top